The trajectory of Viagra presents a intricate picture for shareholders. While the initial launch generated substantial returns, the end of its patent opened the door to off-brand versions, dramatically eroding sales. This creates a unique challenge for drug manufacturers relying on comparable blockbuster medications, suggesting that a careless stak

The history of Viagra, and its creator copyright, presents a complex case study for investors. At first a blockbuster drug, producing billions in revenue , its exclusivity period created a wave of generic competition , significantly diminishing its dominance. While some businesses may attempt to capitalize on related treatments , the current landsc